Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3191313 | Annals of Allergy, Asthma & Immunology | 2013 | 4 Pages |
Abstract
Clinical experience and recent evidence suggest that optimal treatment of patients with PIDD involves individualizing IgG treatment to identify the optimal IgG serum levels that are required for each patient to become free of recurrent infection or pneumonia instead of trying to achieve a single optimal serum IgG level for all patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Vincent R. MD,